These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2616254)

  • 1. Pharmacokinetics of a single dose of ofloxacin in healthy elderly subjects using noncompartmental and compartmental models.
    Rademaker CM; Jones RW; Notarianni LJ; van Dijk A; Glerum JH; Verhoef J
    Pharm Weekbl Sci; 1989 Dec; 11(6):224-8. PubMed ID: 2616254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ofloxacin in elderly patients and in healthy young subjects.
    Molinaro M; Villani P; Regazzi MB; Rondanelli R; Doveri G
    Eur J Clin Pharmacol; 1992; 43(1):105-7. PubMed ID: 1505603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of ofloxacin. An overview.
    Flor S
    Am J Med; 1989 Dec; 87(6C):24S-30S. PubMed ID: 2603892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Renal differential aging processes and ofloxacin pharmacokinetics in the elderly].
    Corvaisier S; Bleyzac N; De Montclos M; Druguet M; Albrand G; Carret G; Maire P
    Therapie; 1999; 54(2):223-31. PubMed ID: 10394258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ofloxacin pharmacokinetics in chronic renal failure and dialysis.
    Lameire N; Rosenkranz B; Malerczyk V; Lehr KH; Veys N; Ringoir S
    Clin Pharmacokinet; 1991 Nov; 21(5):357-71. PubMed ID: 1773550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical pharmacokinetics of levofloxacin.
    Fish DN; Chow AT
    Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetics of ofloxacin in the elderly (65-85 years) with normal renal function after a single oral dose of 200 mg].
    Veyssier P; Fourtillan JB; Modai J; Couet W; Lefebvre MA; Darchis JP; Vincent Du Laurier M; Bryskier A
    Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):596-9. PubMed ID: 3534750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of ofloxacin in severe chronic renal failure.
    Bandai H; Tsubakihara Y; Yamato E; Yokoyama K; Okada N; Nakanishi I; Iida N
    Clin Ther; 1989; 11(2):210-8. PubMed ID: 2736567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose related pharmacokinetics of ofloxacin in healthy volunteers.
    Immanuel C; Hemanthkumar AK; Gurumurthy P; Venkatesan P
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):1017-22. PubMed ID: 12475149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models.
    Dudley MN; Ericson J; Zinner SH
    Antimicrob Agents Chemother; 1987 Nov; 31(11):1782-6. PubMed ID: 3435125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of ofloxacin after single and multiple intravenous infusions in healthy subjects.
    Farinotti R; Trouvin JH; Bocquet V; Vermerie N; Carbon C
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1590-2. PubMed ID: 3190187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence study of a fixed dose combination of nitazoxanide and ofloxacin in Indian healthy volunteers.
    Agarwal S; Solomon WD; Gowda KV; Selvan PS; Ghosh D; Sarkar AK; Chattaraj TK; Pal TK
    Arzneimittelforschung; 2007; 57(10):679-83. PubMed ID: 18074762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral pharmacokinetics and ascitic fluid penetration of ofloxacin in cirrhosis.
    Silvain C; Bouquet S; Breux JP; Becq-Giraudon B; Beauchant M
    Eur J Clin Pharmacol; 1989; 37(3):261-5. PubMed ID: 2612541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and pharmacokinetics of single dose intravenous ofloxacin in healthy volunteers.
    Guay D; Tack K; Flor S
    Int J Clin Pharmacol Res; 1991; 11(5):203-9. PubMed ID: 1814841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacokinetics of intravenous ofloxacin and ciprofloxacin.
    Lode H; Höffken G; Olschewski P; Sievers B; Kirch A; Borner K; Koeppe P
    J Antimicrob Chemother; 1988 Sep; 22 Suppl C():73-9. PubMed ID: 3182465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects.
    Marier JF; Ducharme MP; DiMarco M; Di Spirito M; Morelli G; Tippabhotla SK; Badri N; Rampal A; Monif T
    Clin Ther; 2006 Dec; 28(12):2070-80. PubMed ID: 17296463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment.
    Flor S; Guay D; Opsahl J; Tack K; Matzke G
    Int J Clin Pharmacol Res; 1991; 11(3):115-21. PubMed ID: 1809697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
    Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY
    J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ketoprofen (NSAID) on the pharmacokinetics of pefloxacin and ofloxacin in healthy volunteers.
    Fillastre JP; Leroy A; Borsa-Lebas F; Etienne I; Gy C; Humbert G
    Drugs Exp Clin Res; 1992; 18(11-12):487-92. PubMed ID: 1308475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients.
    Kampf D; Borner K; Pustelnik A
    Eur J Clin Pharmacol; 1992; 42(1):95-9. PubMed ID: 1541323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.